[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4553 Introduced in House (IH)]

<DOC>






116th CONGRESS
  1st Session
                                H. R. 4553

To expand the tropical disease product priority review voucher program 
   to encourage treatments for the Middle East respiratory syndrome, 
                     Nipah, and Rift Valley fever.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           September 27, 2019

 Mr. Brendan F. Boyle of Pennsylvania (for himself, Mr. Marshall, Mr. 
 Veasey, and Mr. Fortenberry) introduced the following bill; which was 
            referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
To expand the tropical disease product priority review voucher program 
   to encourage treatments for the Middle East respiratory syndrome, 
                     Nipah, and Rift Valley fever.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Adding Epidemic Diseases to the FDA 
Priority Review Voucher Program Act''.

SEC. 2. EXPANDING TROPICAL DISEASE PRODUCT PRIORITY REVIEW VOUCHER 
              PROGRAM TO ENCOURAGE TREATMENTS FOR MIDDLE EAST 
              RESPIRATORY SYNDROME, NIPAH, AND RIFT VALLEY FEVER.

    Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 360n(a)(3)) is amended--
            (1) by redesignating subparagraph (S) as subparagraph (V); 
        and
            (2) by inserting after subparagraph (R) the following:
                    ``(S) Middle East respiratory syndrome.
                    ``(T) Nipah.
                    ``(U) Rift Valley fever.''.
                                 <all>